Regeneron Pharmaceuticals (REGN) Common Equity (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Common Equity of $31.7 billion for Q2 2026, up 5.92% year-over-year from $29.9 billion in Q2 2025, and up 0.92% quarter-over-quarter from $31.4 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Common Equity (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $31.7 billion for Q2 2026.
- In Q2 2026, Common Equity rose 5.92% year-over-year to $31.7 billion; the TTM figure through Jun 2026 stood at $31.7 billion (up 5.92% YoY), while the FY2025 annual figure was $31.3 billion, up 6.48% from the prior year.
- Common Equity for Q2 2026 stood at $31.7 billion, up from $31.4 billion in the prior quarter.
- The five-year high for Common Equity was $31.7 billion in Q2 2026, with the low at $19.9 billion in Q1 2022.
- The 5-year median for Common Equity is $27.6 billion (2024), against an average of $26.8 billion.
- The sharpest annual moves came in 2022 and 2025: Common Equity surged 66.27% in 2022, then rose 5.56% in 2025.
- Regeneron Pharmaceuticals' Common Equity stood at $22.7 billion in 2022, then gained by 14.6% to $26.0 billion in 2023, then climbed by 13.02% to $29.4 billion in 2024, then climbed by 6.48% to $31.3 billion in 2025, then increased by 1.45% to $31.7 billion in 2026.
- Business Quant data shows REGN's Common Equity at $31.7 billion in Q2 2026, $31.4 billion in Q1 2026, and $31.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.71 Bn |
| Mar 31, 2026 | 31.42 Bn |
| Dec 31, 2025 | 31.26 Bn |
| Sep 30, 2025 | 30.96 Bn |
| Jun 30, 2025 | 29.94 Bn |
| Mar 31, 2025 | 29.39 Bn |
| Dec 31, 2024 | 29.35 Bn |
| Sep 30, 2024 | 29.33 Bn |
| Jun 30, 2024 | 28.21 Bn |
| Mar 31, 2024 | 26.99 Bn |
| Dec 31, 2023 | 25.97 Bn |
| Sep 30, 2023 | 24.90 Bn |
| Jun 30, 2023 | 24.02 Bn |
| Mar 31, 2023 | 23.50 Bn |
| Dec 31, 2022 | 22.66 Bn |
| Sep 30, 2022 | 21.44 Bn |
| Jun 30, 2022 | 20.69 Bn |
| Mar 31, 2022 | 19.91 Bn |
| Dec 31, 2021 | 18.77 Bn |
| Sep 30, 2021 | 17.26 Bn |